Loading…
Develops bispecific T-cell receptor (TCR) therapies for cancer, led by approved treatment Kimmtrak for melanoma.
Develops bispecific T-cell receptor (TCR) therapies for cancer, led by approved treatment Kimmtrak for melanoma.
Earns most of its revenue from Kimmtrak, an infusion approved in 2022 for uveal melanoma (an eye cancer), but only for patients with a particular tissue type, which limits who can be treated. The rest of the pipeline, including drugs aimed at the PRAME cancer marker, is still in trials.
Moat: narrow (IP / patents, process know-how). Proprietary ImmTAC bispecific TCR platform behind the first approved TCR therapeutic, hard to replicate.
Headquarters: Oxfordshire, UK · Founded: 2008 · Employees: 524
Size Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh (IMCR) is a United States Health Care company (Biotechnology) with a market value of $1.60B, the 1948th largest of 3,117 United States companies the cockpit tracks. Shares closed at $30.99 on 6 Nov 2026.
Performance Over six months the shares gained 4.8%, against -15.4% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 20.2% over the last twelve months (peer median +27.5%); the operating margin is -5.2% (peer median -63.5%).
Valuation It trades at 2.7× enterprise value to sales against a peer median of 19.4× (3rd cheapest of 18).
Credit Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh has 1 bond outstanding ($402M).
Short interest Short interest is 15.2% of the free float (15 Oct 2026).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $430M | $401M | $310M | $250M | $177M |
| Revenue growth | — | +29% | +24% | +41% | — |
| Gross profit | $422M | $393M | $303M | $245M | $169M |
| EBITDA | -$18.9M | -$42.2M | -$66.3M | -$55.8M | -$56.4M |
| Net income | -$18.1M | -$35.6M | -$51.1M | -$55.5M | -$50.8M |
| Free cash flow | -$41.4M | -$15.1M | $20.9M | -$2.49M | -$38.6M |
| Capital expenditure | $6.20M | $4.35M | $5.18M | $5.45M | $2.71M |
| Total debt | $435M | $437M | $433M | $84.0M | $83.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | $1.60B | +5% | +20% | -5% | 2.7× | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| Roche RO.SW | $385B | +22% | -1% | 31% | 5.6× | 0.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IMCR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.5% | -9.3% | 4th highest of 21 |
| 6-month return | +4.8% | -15.4% | 5th highest of 19 |
| Distance from 52-week high | -23.9% | -43.3% | 5th highest of 21 |
| Revenue growth (TTM) | +20.2% | +27.5% | 8th lowest of 19 |
| Operating margin | -5.2% | -63.5% | 9th highest of 19 |
| EV / Sales | 2.7× | 19.4× | 3rd cheapest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 8.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh has 1 bond outstanding with $402M face value.